We disagree which is ok. I just believe that demand must be addressed by the safest (closed system) and least labor intensive manufacturing or demand will easily outstrip supply. Because of this I believe Edens must be very close, at a minimum, to being approved alongside of the manual system. I’m pretty sure regulators are going to be rather insistent about this because of the expected impact on the cancer treatment market with a tissue agnostic designation. Best wishes.
News 
Market Data 
Discover 
